Related Experiment Video
Updated: Jul 22, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Antibody drug conjugates for glioblastoma: current progress towards clinical use
Hui K Gan1,2,3,4,5, Sagun Parakh1,2,3,4, Laura D Osellame2,4,6
1Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.
Introduction:
Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these tumors.
Areas Covered:
This review will cover all the key classes of ADCs which have been tested in primary brain tumors, including commentary on the major trials to date. The efficacy of these trials, as well as their limitations, will put in context of the overall landscape of drug development in brain tumors. Importantly, this review will summarize key learnings and insights from these trials that help provide the basis for rational ways in which these drugs can be effectively and appropriate developed for patients with primary brain tumors.
Expert Opinion:
ADC development in brain tumors has occurred in two major phases to date. Key learnings from previous trials provide a strong rationale for the continued development of these drugs for primary brain tumors. However, the unique biology of these tumors requires development strategies specifically tailored to maximize their optimal development.
Insights
Antibody drug conjugates (ADCs) are effective cancer therapies. This review explores ADC use in brain tumors, detailing past trials and future strategies for optimized development.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, merging targeted delivery with potent payloads.
- Their application in treating various cancers is well-established, prompting investigation into their efficacy for brain tumors.
Purpose of the Study:
- To review the current landscape of Antibody drug conjugate (ADC) development in primary brain tumors.
- To analyze the efficacy and limitations of major clinical trials involving ADCs in brain tumor treatment.
- To extract key learnings and insights to inform future rational development strategies for ADCs in brain tumors.
Main Methods:
- Comprehensive literature review of Antibody drug conjugate (ADC) classes tested in primary brain tumors.
- Analysis of major clinical trial data, focusing on efficacy and limitations.
- Synthesis of findings to identify key learnings and propose tailored development strategies.
Main Results:
- Two major phases of Antibody drug conjugate (ADC) development in brain tumors have been identified.
- Previous trials provide a strong rationale for continued ADC development in this area.
- The unique biological characteristics of brain tumors necessitate specialized development approaches.
Conclusions:
- Antibody drug conjugates (ADCs) show promise as a therapeutic class for brain tumors.
- Key learnings from past trials are crucial for advancing ADC development.
- Tailored strategies are essential to maximize the potential of ADCs in treating primary brain tumors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy